Here we report, at the peak of the immune response, spike-specific CD8+ T cells by AIM or ICS assays were detected in 88% of subjects receiving low-dose mRNA-1273, which is a CD8+ T cell response rate equivalent to that of COVID-19 cases (21, 22, 26, 31). The gene discussed is CD8A; the disease is COVID-19.